NFL agrees to end race-based dementia testing for concussion settlements in $1 billion agreement

Credit: CBS
Credit: CBS

The NFL and lawyers for thousands of retired NFL players have reached an agreement to end race-based adjustments in dementia testing in the $1 billion settlement of concussion claims, according to a proposed deal filed Wednesday in federal court.

The revised testing plan follows public outrage over the use of “race-norming,” a practice that came to light only after two former NFL players filed a civil rights lawsuit over it last year. The adjustments, critics say, may have prevented hundreds of Black players suffering from dementia to win awards that average $500,000 or more.

The Black retirees will now have the chance to have their tests rescored or, in some cases, seek a new round of cognitive testing, according to the settlement.

Follow the latest news and policy debates on sustainable agriculture, biomedicine, and other ‘disruptive’ innovations. Subscribe to our newsletter.

 details of which were first reported in The New York Times on Wednesday.

The vast majority of the league’s players — 70% of active players and more than 60% of living retirees — are Black. So the changes are expected to be significant, and potentially costly for the NFL.

“No race norms or race demographic estimates — whether Black or white — shall be used in the settlement program going forward,” the proposal said.

This is an excerpt. Read the original post here.

{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}

Related Articles

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Infographic: Global regulatory and health research agencies on whether glyphosate causes cancer

Does glyphosate—the world's most heavily-used herbicide—pose serious harm to humans? Is it carcinogenic? Those issues are of both legal and ...

Most Popular

Screenshot-2026-03-13-at-12.14.04-PM
The FDA wants to make many popular prescription drugs OTC—a great idea. Here’s why it’s unlikely to happen
Screenshot-2026-05-04-at-12.54.32-PM
How Utah became the country’s supplement capital  — and a haven for unregulated, ineffective and fake products
Screenshot-2026-04-20-at-2.26.27-PM
Viewpoint — Food-fear world: The latest activist scientists campaign: Cancer-causing additives
Screenshot-PM-24
Viewpoint: The herbicide glyphosate isn’t perfect. Banning it would be far worse.
images
The never-ending GMO debate: Pros and cons
Screenshot-2026-05-01-at-11.56.24-AM
‘Science moves forward when people are willing to think differently’: Memories of DNA maverick Craig Venter
Screenshot-2026-04-30-at-2.19.37-PM
5 myths about summer dehydration that could damage your health — or even kill you
Screenshot-2026-04-03-at-11.15.51-AM
Paraben panic: How a flawed study, media hype, and chemophobia convinced the public of the danger of one of the safest classes of preservatives
bigstock opioids on chalkboard with rol
GLP podcast: 'Safe injection sites': enabling drug addiction or saving lives?
ChatGPT-Image-May-1-2026-02_20_13-PM
How RFK, Jr.’s false vaccine claims are holding up $600 million to fight diseases in poor countries
79d03212-2508-45d0-b427-8e9743ff6432
Viewpoint: The Casey Means hustle—Wellness woo opportunism dressed up as medical wisdom
glp menu logo outlined

Get news on human & agricultural genetics and biotechnology delivered to your inbox.